Acceleron Pharma’s ACE-536 Preclinical Data Presentation Selected for Best Abstract at 12th International Symposium on Myelodysplastic Syndromes

Published: May 10, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan hematologic diseases, today announced that preclinical research conducted by Acceleron scientists on the ACE-536 program received the Tito Bastianello Award for best abstract and oral presentation at the 12th International Symposium on Myelodysplastic Syndromes in Berlin, Germany. Acceleron presented data on the effects of its investigational protein therapeutic, ACE-536, on correcting anemia and ineffective erythropoiesis in an animal model of myelodysplastic syndromes (MDS). In a separate poster presentation, Acceleron also presented a description of its ongoing phase 2 study (“PACE-MDS”) of ACE-536 in patients with MDS. ACE-536 increases red blood cells (RBC) and hemoglobin levels through a novel mechanism distinct from that of currently available anemia therapies, such as erythropoiesis-stimulating agents. ACE-536 is being developed by Acceleron as part of a global collaboration with Celgene Corporation (NASDAQ: CELG).

Help employers find you! Check out all the jobs and post your resume.

Back to news